Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

That means that it is possible for African states to buy the Tau without an expensive new turret and simply repurpose their existing systems. As a consequence, the Tau comes in at a markedly lower ...